Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models
- PMID: 20028824
- PMCID: PMC2826009
- DOI: 10.1128/AAC.01114-09
Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models
Abstract
Colistin is increasingly used as last-line therapy against Gram-negative pathogens. The pharmacokinetic (PK)/pharmacodynamic (PD) index that best correlates with the efficacy of colistin remains undefined. The activity of colistin against three strains of Pseudomonas aeruginosa was studied in neutropenic mouse thigh and lung infection models. The PKs of unbound colistin were determined from single-dose PK studies together with extensive plasma protein binding analyses. Dose-fractionation studies were conducted over 24 h with a dose range of 5 to 160 mg/kg of body weight/day. The bacterial burden in the thigh or lung was measured at 24 h after the initiation of treatment. Relationships between antibacterial effect and measures of exposure to unbound (f) colistin (area under the concentration-time curve [fAUC/MIC], maximum concentration of drug in plasma [fC(max)]/MIC, and the time that the concentration in plasma is greater than the MIC [fT > MIC]) were examined by using an inhibitory sigmoid maximum-effect model. Nonlinearity in the PKs of colistin, including its plasma protein binding, was observed. The PK/PD index that correlated best with its efficacy was fAUC/MIC in both the thigh infection model (R(2) = 87%) and the lung infection model (R(2) = 89%). The fAUC/MIC targets required to achieve 1-log and 2-log kill against the three strains were 15.6 to 22.8 and 27.6 to 36.1, respectively, in the thigh infection model, while the corresponding values were 12.2 to 16.7 and 36.9 to 45.9 in the lung infection model. The findings of this in vivo study indicate the importance of achieving adequate time-averaged exposure to colistin. The results will facilitate efforts to define the more rational design of dosage regimens for humans.
Figures




Similar articles
-
fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.J Antimicrob Chemother. 2010 Sep;65(9):1984-90. doi: 10.1093/jac/dkq226. Epub 2010 Jun 23. J Antimicrob Chemother. 2010. PMID: 20573659 Free PMC article.
-
New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.J Antimicrob Chemother. 2015 Dec;70(12):3291-7. doi: 10.1093/jac/dkv267. Epub 2015 Aug 27. J Antimicrob Chemother. 2015. PMID: 26318190
-
Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.Antimicrob Agents Chemother. 2017 Feb 23;61(3):e02025-16. doi: 10.1128/AAC.02025-16. Print 2017 Mar. Antimicrob Agents Chemother. 2017. PMID: 28031207 Free PMC article.
-
In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models.Antimicrob Agents Chemother. 2019 Aug 23;63(9):e02031-18. doi: 10.1128/AAC.02031-18. Print 2019 Sep. Antimicrob Agents Chemother. 2019. PMID: 31262762 Free PMC article.
-
In vitro Pharmacodynamics and PK/PD in Animals.Adv Exp Med Biol. 2019;1145:105-116. doi: 10.1007/978-3-030-16373-0_8. Adv Exp Med Biol. 2019. PMID: 31364074 Review.
Cited by
-
Autophagy regulates colistin-induced apoptosis in PC-12 cells.Antimicrob Agents Chemother. 2015 Apr;59(4):2189-97. doi: 10.1128/AAC.04092-14. Epub 2015 Feb 2. Antimicrob Agents Chemother. 2015. PMID: 25645826 Free PMC article.
-
Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys.Pharm Res. 2015 Oct;32(10):3403-14. doi: 10.1007/s11095-015-1716-0. Epub 2015 Jun 4. Pharm Res. 2015. PMID: 26040660
-
Anti-infective Medicines Use in Children and Neonates With Pre-existing Kidney Dysfunction: A Systematic Review.Front Pediatr. 2022 Apr 26;10:868513. doi: 10.3389/fped.2022.868513. eCollection 2022. Front Pediatr. 2022. PMID: 35558367 Free PMC article.
-
Concentration-Dependent Activity of Pazufloxacin against Pseudomonas aeruginosa: An In Vivo Pharmacokinetic/Pharmacodynamic Study.Antibiotics (Basel). 2022 Jul 21;11(7):982. doi: 10.3390/antibiotics11070982. Antibiotics (Basel). 2022. PMID: 35884236 Free PMC article.
-
Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.Drugs. 2014 Mar;74(3):377-87. doi: 10.1007/s40265-014-0181-0. Drugs. 2014. PMID: 24510624 Review.
References
-
- Bergen, P. J., J. Li, R. L. Nation, J. D. Turnidge, K. Coulthard, and R. W. Milne. 2008. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 61:636-642. - PubMed
-
- Boucher, H. W., G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg, and J. Bartlett. 2009. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. - PubMed
-
- Bradley, J. S., R. Guidos, S. Baragona, J. G. Bartlett, E. Rubinstein, G. G. Zhanel, M. D. Tino, D. L. Pompliano, F. Tally, and P. Tipirneni. 2007. Anti-infective research and development—problems, challenges, and solutions. Lancet Infect. Dis. 7:68-78. - PubMed
-
- Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement (M100-S17). Clinical and Laboratory Standards Institute, Wayne, PA.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous